News Rare disease drug Strensiq too expensive, says NICE Alexion's new rare disease treatment Strensiq has been rejected by England's health watchdog NICE in draft guidance.
News Alexion must ‘explain’ high cost of Soliris, says NICE NICE has concluded that orphan drug Soliris is highly effective in treating rare disease aHUS – but says it won't approve the drug yet, asking pharma company Alexion to first 'explain' how
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
